All articles
CagriSema: The New GLP 1 and Amylin Combination That May Transform Obesity Treatment
Reading time:
7 min
Weight loss
Get expert guidance and a personalized care plan designed around you.
How CagriSema Compares With Current GLP-1 Medications
One of the biggest questions people have is how CagriSema compares with medications such as Wegovy, Zepbound, or Mounjaro. Because CagriSema includes semaglutide, many of the benefits will feel familiar to people who have used GLP 1s before. The difference is the added amylin pathway, which appears to enhance fullness and decrease cravings even more.
In clinical studies, semaglutide alone can produce weight reductions of around 15 percent in many people. Early CagriSema trials show weight loss that matches or exceeds these results at comparable time points. CagriSema is especially interesting for people who may have plateaued on existing medications or who live with metabolic conditions like diabetes that make weight loss more difficult.
While tirzepatide (Zepbound and Mounjaro) currently leads in terms of average weight loss in approved medications, CagriSema could become a strong competitor once Phase 3 results are released.
What Makes Amylin Analogues Different
Amylin analogues represent an important next frontier for obesity treatment. While GLP 1s work on appetite, digestion, and insulin, amylin analogues influence fullness and food reward in a deeper way. They help people feel satisfied after smaller meals and reduce the desire to graze between meals. These effects may help individuals experience fewer cravings and fewer overeating episodes.
Cagrilintide is the first next-generation amylin analogue to be tested at scale. Researchers believe that amylin analogues may eventually be paired with multiple GLP 1s, not only semaglutide, creating even more combination therapies in the future.
Potential Benefits Beyond Weight Loss
Although weight loss is the most visible effect of GLP 1 and amylin medications, CagriSema may also support deeper metabolic improvements. Early trials show promising changes in blood sugar, insulin resistance, inflammation, and liver fat. People with type 2 diabetes saw improvements in A1c, fasting glucose, and markers of metabolic health.
Because amylin and GLP 1 signaling influence several metabolic systems at once, researchers expect CagriSema to have broader benefits than weight alone once larger trials are completed. These areas may include cardiovascular health, fatty liver disease, and inflammatory markers.
When Will CagriSema Be Available?
CagriSema is currently in Phase 3 clinical trials. If results remain strong and the FDA review process proceeds on schedule, approval could occur sometime between 2026 and 2027. The timeline will depend on safety data, final trial outcomes, and regulatory review. While CagriSema is a highly anticipated injectable, researchers are also fast-tracking other delivery methods; for instance, orforglipron, a daily oral GLP-1 pill, is also expected to potentially hit the market by 2026.
If you want to explore currently available GLP 1 medications, you can check here.
Who Might Benefit Most From CagriSema?
While studies are ongoing, early insights suggest that CagriSema may be especially helpful for people who have struggled with appetite regulation or intense cravings. Individuals with insulin resistance, type 2 diabetes, or previous weight loss plateaus may also benefit. People who have found GLP 1s helpful but still have remaining hunger or cravings may respond well to the added amylin support.
Because CagriSema affects several metabolic pathways at once, it may be useful for individuals with complex metabolic challenges that have not responded fully to single pathway therapies.
How CagriSema Could Transform the Future of Obesity Treatment
CagriSema has the potential to reshape the next decade of obesity care. The current generation of GLP 1 medications has already changed how clinicians think about weight, metabolism, and long term health, but researchers have always known that the biology of appetite is more complex than a single hormone pathway. CagriSema represents the next step forward because it layers together two powerful metabolic signals that work in different but complementary ways.
If larger trials confirm the early results, CagriSema may offer deeper weight loss for people who previously struggled on single-agent therapies. It may also help those who continue to feel hungry or experience cravings while taking GLP 1 medications alone. By addressing appetite, fullness, insulin regulation, and food reward at the same time, CagriSema could make weight loss more sustainable, predictable, and psychologically easier for many patients.
This dual-hormone approach may become a new standard in obesity care. Just as combination treatments transformed fields like diabetes, HIV, and hypertension, CagriSema could open the door to a new wave of multi-pathway medications designed to support long term metabolic health. As more amylin analogues enter development, combination therapies may become a defining part of obesity treatment in the years ahead.
Clinicians are also looking at how CagriSema might help with related conditions such as fatty liver disease, insulin resistance, and cardiometabolic risk. Because these conditions often overlap with obesity, a medication that targets multiple pathways at once could become an important tool for broad metabolic care.
FAQs
What is CagriSema?
CagriSema is a combination of semaglutide and cagrilintide, designed to support weight loss and metabolic health through two complementary pathways.
How does it work?
It combines GLP 1 and amylin activity, which together reduce appetite, improve fullness, regulate blood sugar, and support metabolic balance.
Is CagriSema stronger than semaglutide alone?
Early studies show greater weight loss and metabolic improvements with CagriSema compared to semaglutide alone.
When will CagriSema be available?
Approval is expected in 2026 or 2027 depending on trial results and FDA review.
Will Mochi offer CagriSema?
Mochi intends to evaluate the final prescribing information and offer the medication once FDA approval is granted.
Check Your Eligibility
If you are interested in GLP 1 treatment or want to learn about current options available before CagriSema is released, you can start with Mochi’s eligibility questionnaire. It takes only a few minutes and helps our clinical team understand your goals, your health history, and whether GLP 1 therapy may be a good fit. Check your eligibility here.
References:
Astrup, A., Carraro, R., Finer, N., Harper, A., et al. (2021). Safety and weight loss effects of cagrilintide in people with obesity. The Lancet, 397(10290), 1737 to 1748.
Sjöström, L., Rissanen, A., Andersen, T., et al. (2023). Phase 2 trial of CagriSema in adults with overweight or obesity. Diabetes, Obesity and Metabolism, 25(8), 2091 to 2102.
Bain, S. C., et al. (2022). Mechanisms of action of amylin analogues and GLP 1 receptor agonists. Obesity Reviews, 23(5), e13492.
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
Share this post
Weight loss
More articles
Read next
For iOS & Android
